Published in J Gen Virol on September 21, 2011
Emergence of cowpox: study of the virulence of clinical strains and evaluation of antivirals. PLoS One (2013) 0.97
Comparison of host cell gene expression in cowpox, monkeypox or vaccinia virus-infected cells reveals virus-specific regulation of immune response genes. Virol J (2013) 0.78
Small particle aerosol inoculation of cowpox Brighton Red in rhesus monkeys results in a severe respiratory disease. Virology (2015) 0.75
Poxviruses and immune evasion. Annu Rev Immunol (2001) 4.80
Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox. J Virol (2004) 2.72
The Pathological Anatomy and Histology of Variola. J Med Res (1904) 2.70
Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. Proc Natl Acad Sci U S A (2010) 2.69
The pathology of experimental aerosolized monkeypox virus infection in cynomolgus monkeys (Macaca fascicularis). Lab Invest (2001) 2.38
Virulence differences between monkeypox virus isolates from West Africa and the Congo basin. Virology (2005) 2.36
Exploring the potential of variola virus infection of cynomolgus macaques as a model for human smallpox. Proc Natl Acad Sci U S A (2004) 2.36
Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge. J Infect Dis (2000) 2.29
Breaking the deadlock over destruction of the smallpox virus stocks. Biosecur Bioterror (2011) 2.21
Human monkeypox: an emerging zoonotic disease. Future Microbiol (2007) 2.15
Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine (2001) 2.06
Cowpox virus infection: an emerging health threat. Curr Opin Infect Dis (2008) 1.85
Development and use of a vaccinia virus neutralization assay based on flow cytometric detection of green fluorescent protein. J Virol (2003) 1.73
Clinical manifestations of human monkeypox influenced by route of infection. J Infect Dis (2006) 1.71
Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. Antimicrob Agents Chemother (2009) 1.52
The morbid anatomy of smallpox. Doc Med Geogr Trop (1952) 1.47
Poxvirus Bioinformatics Resource Center: a comprehensive Poxviridae informational and analytical resource. Nucleic Acids Res (2005) 1.47
Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus. Proc Natl Acad Sci U S A (2008) 1.31
Animal models of orthopoxvirus infection. Vet Pathol (2010) 1.29
A mouse model of aerosol-transmitted orthopoxviral disease: morphology of experimental aerosol-transmitted orthopoxviral disease in a cowpox virus-BALB/c mouse system. Arch Pathol Lab Med (2000) 1.26
Comparative analysis of monkeypox virus infection of cynomolgus macaques by the intravenous or intrabronchial inoculation route. J Virol (2010) 1.25
Smallpox vaccine does not protect macaques with AIDS from a lethal monkeypox virus challenge. J Infect Dis (2005) 1.17
A novel highly reproducible and lethal nonhuman primate model for orthopox virus infection. PLoS One (2010) 1.11
A novel respiratory model of infection with monkeypox virus in cynomolgus macaques. J Virol (2011) 1.11
Cowpox virus transmission from rats to monkeys, the Netherlands. Emerg Infect Dis (2006) 1.10
The cause of death in smallpox: an examination of the pathology record. Mil Med (2002) 1.09
Killing a killer: what next for smallpox? PLoS Pathog (2010) 0.99
Fatal poxvirus outbreak in a colony of New World monkeys. Vet Pathol (2006) 0.97
Extensive lesions of monkeypox in a prairie dog (Cynomys sp). Vet Pathol (2004) 0.96
Cowpox virus infection of cynomolgus macaques as a model of hemorrhagic smallpox. Virology (2011) 0.90
Genome-based phylogeny of poxvirus. Intervirology (2006) 0.90
Why not destroy the remaining smallpox virus stocks? Vaccine (2011) 0.78
Monkeypox virus in liver and spleen of child in Gabon. Lancet (1988) 0.78
Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med (2005) 6.77
Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA (2002) 6.59
Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature (2003) 6.35
Prospects for a dengue virus vaccine. Nat Rev Microbiol (2007) 4.99
The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J Virol (2003) 4.73
Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am J Pathol (2003) 4.67
Exotic emerging viral diseases: progress and challenges. Nat Med (2004) 4.54
Ovarian tumor domain-containing viral proteases evade ubiquitin- and ISG15-dependent innate immune responses. Cell Host Microbe (2007) 4.14
Proposal for a revised taxonomy of the family Filoviridae: classification, names of taxa and viruses, and virus abbreviations. Arch Virol (2010) 3.77
Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature (2004) 3.65
Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet (2003) 3.57
Panmicrobial oligonucleotide array for diagnosis of infectious diseases. Emerg Infect Dis (2007) 3.51
Mechanisms underlying coagulation abnormalities in ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. J Infect Dis (2003) 3.33
Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment. Lancet (2006) 3.15
Overlapping motifs (PTAP and PPEY) within the Ebola virus VP40 protein function independently as late budding domains: involvement of host proteins TSG101 and VPS-4. J Virol (2003) 3.05
Contribution of ebola virus glycoprotein, nucleoprotein, and VP24 to budding of VP40 virus-like particles. J Virol (2004) 2.92
Reverse genetics with a full-length infectious cDNA of severe acute respiratory syndrome coronavirus. Proc Natl Acad Sci U S A (2003) 2.82
Development of a new vaccine for the prevention of Lassa fever. PLoS Med (2005) 2.71
Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proc Natl Acad Sci U S A (2007) 2.69
Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells. Am J Pathol (2003) 2.66
Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS Pathog (2007) 2.64
Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med (2006) 2.64
Evaluation of perceived threat differences posed by filovirus variants. Biosecur Bioterror (2011) 2.62
rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers. J Infect Dis (2005) 2.46
Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever. J Infect Dis (2007) 2.44
Virulence differences between monkeypox virus isolates from West Africa and the Congo basin. Virology (2005) 2.36
Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody. J Virol (2002) 2.31
Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg Infect Dis (2002) 2.26
Generation of eGFP expressing recombinant Zaire ebolavirus for analysis of early pathogenesis events and high-throughput antiviral drug screening. Virology (2005) 2.25
Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference. J Infect Dis (2006) 2.19
Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species. PLoS Pathog (2010) 2.18
Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog (2008) 2.10
Proinflammatory response during Ebola virus infection of primate models: possible involvement of the tumor necrosis factor receptor superfamily. Immunol Lett (2002) 2.06
Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses. J Virol (2011) 1.99
Replication of SARS coronavirus administered into the respiratory tract of African Green, rhesus and cynomolgus monkeys. Virology (2004) 1.91
The host response to smallpox: analysis of the gene expression program in peripheral blood cells in a nonhuman primate model. Proc Natl Acad Sci U S A (2004) 1.85
CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. Nat Med (2011) 1.83
Smallpox and pan-orthopox virus detection by real-time 3'-minor groove binder TaqMan assays on the roche LightCycler and the Cepheid smart Cycler platforms. J Clin Microbiol (2004) 1.77
Recombinant newcastle disease virus expressing a foreign viral antigen is attenuated and highly immunogenic in primates. J Virol (2005) 1.72
Framework for leadership and training of Biosafety Level 4 laboratory workers. Emerg Infect Dis (2008) 1.66
Biochemical and functional characterization of the Ebola virus VP24 protein: implications for a role in virus assembly and budding. J Virol (2003) 1.60
Virus nomenclature below the species level: a standardized nomenclature for natural variants of viruses assigned to the family Filoviridae. Arch Virol (2012) 1.59
Depletion of peripheral blood T lymphocytes and NK cells during the course of ebola hemorrhagic Fever in cynomolgus macaques. Viral Immunol (2004) 1.55
Pathologic findings associated with delayed death in nonhuman primates experimentally infected with Zaire Ebola virus. J Infect Dis (2007) 1.52
A trade-off in replication in mosquito versus mammalian systems conferred by a point mutation in the NS4B protein of dengue virus type 4. Virology (2003) 1.51
The open reading frame 3 gene of hepatitis E virus contains a cis-reactive element and encodes a protein required for infection of macaques. J Virol (2005) 1.50
Trigger events: enviroclimatic coupling of Ebola hemorrhagic fever outbreaks. Am J Trop Med Hyg (2004) 1.45
Hepatitis E virus in rats, Los Angeles, California, USA. Emerg Infect Dis (2011) 1.45
The soy isoflavone genistein decreases adipose deposition in mice. Endocrinology (2003) 1.43
Protection from lethal infection is determined by innate immune responses in a mouse model of Ebola virus infection. Virology (2003) 1.40
Cynomolgus macaque as an animal model for severe acute respiratory syndrome. PLoS Med (2006) 1.40
Efficient neutralization of anthrax toxin by chimpanzee monoclonal antibodies against protective antigen. J Infect Dis (2006) 1.40
rDEN2/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naïve adults. Hum Vaccin (2006) 1.36
The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteers. Hum Vaccin (2006) 1.35
MassTag polymerase chain reaction for differential diagnosis of viral hemorrhagic fever. Emerg Infect Dis (2006) 1.35
Resolution of primary severe acute respiratory syndrome-associated coronavirus infection requires Stat1. J Virol (2004) 1.34
Paired charge-to-alanine mutagenesis of dengue virus type 4 NS5 generates mutants with temperature-sensitive, host range, and mouse attenuation phenotypes. J Virol (2002) 1.32
Real-time PCR assay to detect smallpox virus. J Clin Microbiol (2003) 1.32
Effects of food processing on masticatory strain and craniofacial growth in a retrognathic face. J Hum Evol (2004) 1.30
Phase I clinical evaluation of rDEN4Delta30-200,201: a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicity. Am J Trop Med Hyg (2008) 1.28
Ebola virus genome plasticity as a marker of its passaging history: a comparison of in vitro passaging to non-human primate infection. PLoS One (2012) 1.28
Influences of glycosylation on antigenicity, immunogenicity, and protective efficacy of ebola virus GP DNA vaccines. J Virol (2006) 1.28
Interferon-β therapy prolongs survival in rhesus macaque models of Ebola and Marburg hemorrhagic fever. J Infect Dis (2012) 1.27
Clinical management of filovirus-infected patients. Viruses (2012) 1.26
Comparative analysis of monkeypox virus infection of cynomolgus macaques by the intravenous or intrabronchial inoculation route. J Virol (2010) 1.25
Clarification and guidance on the proper usage of virus and virus species names. Arch Virol (2010) 1.20
Smallpox research activities: U.S. interagency collaboration, 2001. Emerg Infect Dis (2002) 1.20
The temporal program of peripheral blood gene expression in the response of nonhuman primates to Ebola hemorrhagic fever. Genome Biol (2007) 1.20
Towards a vaccine against Ebola virus. Expert Rev Vaccines (2003) 1.19
Cellular localization and antigenic characterization of crimean-congo hemorrhagic fever virus glycoproteins. J Virol (2005) 1.19
Viral hemorrhagic fevers. Clin Lab Med (2006) 1.18
A proposal to change existing virus species names to non-Latinized binomials. Arch Virol (2010) 1.18
Mutations within potential glycosylation sites in the capsid protein of hepatitis E virus prevent the formation of infectious virus particles. J Virol (2007) 1.16
Experimental therapy of filovirus infections. Antiviral Res (2002) 1.16
Virus nomenclature below the species level: a standardized nomenclature for laboratory animal-adapted strains and variants of viruses assigned to the family Filoviridae. Arch Virol (2013) 1.16
Lymphocyte death in a mouse model of Ebola virus infection. J Infect Dis (2007) 1.12
A novel respiratory model of infection with monkeypox virus in cynomolgus macaques. J Virol (2011) 1.11
Phase 1 trial of the dengue virus type 4 vaccine candidate rDEN4{Delta}30-4995 in healthy adult volunteers. Am J Trop Med Hyg (2009) 1.11
Potential impact of a 2-person security rule on BioSafety Level 4 laboratory workers. Emerg Infect Dis (2009) 1.11
Crimean-Congo hemorrhagic fever: current and future prospects of vaccines and therapies. Antiviral Res (2011) 1.11
Identification of a novel C-terminal cleavage of Crimean-Congo hemorrhagic fever virus PreGN that leads to generation of an NSM protein. J Virol (2007) 1.10
Virus nomenclature below the species level: a standardized nomenclature for filovirus strains and variants rescued from cDNA. Arch Virol (2013) 1.10
In vitro and in vivo mutational analysis of the 3'-terminal regions of hepatitis e virus genomes and replicons. J Virol (2005) 1.09
Taxonomic reorganization of the family Bornaviridae. Arch Virol (2014) 1.09
Role for amino acids 212KLR214 of Ebola virus VP40 in assembly and budding. J Virol (2007) 1.08
Evaluation of monkeypox disease progression by molecular imaging. J Infect Dis (2011) 1.07